There was a nice story on the BBC today about GA101, a new antibody targeting CD20 which is being used to treat CLL. Our own, Professor Chris Fegan gave quotes for the BBC article.
The press release follows very promising results showing that GA101 works better than MabThera/Rituxan as reported in last summer’s press release from Roche, the company developing the agent. There is a video where Chris talks about it here.
The latest data has just been presented at the American Society of Hematology Annual Meeting in New Orleans, USA.